Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication

BACKGROUND: Oncolytic therapy uses live-replicating viruses to improve the immunological status of treated tumors. Critically, while these viruses are known to self-amplify in vivo, clinical oncolytic therapies still appear to display a strong dose dependence and the mechanisms mediating this dose d...

Descripción completa

Detalles Bibliográficos
Autores principales: Flores, Erica B, Aksoy, Bulent A, Bartee, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319776/
https://www.ncbi.nlm.nih.gov/pubmed/32581062
http://dx.doi.org/10.1136/jitc-2020-000804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319776/
https://www.ncbi.nlm.nih.gov/pubmed/32581062
http://dx.doi.org/10.1136/jitc-2020-000804

Ejemplares similares